 CHICAGO--BUSINESS WIRE--Xeris Pharmaceuticals, Inc. Nasdaq: XERS, a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on January 27, 2021, the Compensation Committee of Xeris Board of Directors granted non-qualified stock options for an aggregate of 16,000 shares of its common stock to 38 new employees under Xeris Inducement Equity Plan. Xeris Inducement E 